H2BC8
gene geneOn this page
Also known as H2B/aH2B.1A
Summary
H2BC8 (H2B clustered histone 8, HGNC:4746) is a protein-coding gene on chromosome 6p22.2, encoding Histone H2B type 1-C/E/F/G/I (P62807). Core component of nucleosome.
Histones are basic nuclear proteins that are responsible for the nucleosome structure of the chromosomal fiber in eukaryotes. Nucleosomes consist of approximately 146 bp of DNA wrapped around a histone octamer composed of pairs of each of the four core histones (H2A, H2B, H3, and H4). The chromatin fiber is further compacted through the interaction of a linker histone, H1, with the DNA between the nucleosomes to form higher order chromatin structures. The protein has antibacterial and antifungal antimicrobial activity. This gene is intronless and encodes a replication-dependent histone that is a member of the histone H2B family. Transcripts from this gene lack polyA tails; instead, they contain a palindromic termination element. This gene is found in the large histone gene cluster on chromosome 6p22-p21.3.
Source: NCBI Gene 8339 — RefSeq curated summary.
At a glance
- GWAS associations: 14
- Clinical variants (ClinVar): 14 total
- MANE Select transcript:
NM_003518
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:4746 |
| Approved symbol | H2BC8 |
| Name | H2B clustered histone 8 |
| Location | 6p22.2 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | H2B/a, H2B.1A |
| Ensembl gene | ENSG00000273802 |
| Ensembl biotype | protein_coding |
| OMIM | 602798 |
| Entrez | 8339 |
Gene structure
Transcript identifiers
Ensembl transcripts: 1 — 1 protein_coding
ENST00000541790
RefSeq mRNA: 1 — MANE Select: NM_003518
NM_003518
CCDS: CCDS4594
Canonical transcript exons
ENST00000541790 — 1 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001648136 | 26216200 | 26216688 |
Expression profiles
Bgee: expression breadth ubiquitous, 220 present calls, max score 94.76.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 240.2959 / max 12024.9753, expressed in 1797 samples.
FANTOM5 promoters (4 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 72331 | 218.5480 | 1796 |
| 72330 | 21.2059 | 1558 |
| 72329 | 0.4017 | 118 |
| 72328 | 0.1403 | 62 |
Top tissues by expression
277 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| buccal mucosa cell | CL:0002336 | 94.76 | gold quality |
| thymus | UBERON:0002370 | 88.14 | gold quality |
| corpus epididymis | UBERON:0004359 | 87.40 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 87.16 | gold quality |
| bone marrow cell | CL:0002092 | 87.16 | gold quality |
| adrenal tissue | UBERON:0018303 | 86.88 | gold quality |
| amniotic fluid | UBERON:0000173 | 85.91 | gold quality |
| monocyte | CL:0000576 | 85.08 | gold quality |
| mononuclear cell | CL:0000842 | 84.95 | gold quality |
| leukocyte | CL:0000738 | 83.81 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 83.05 | gold quality |
| caput epididymis | UBERON:0004358 | 82.45 | gold quality |
| colonic epithelium | UBERON:0000397 | 82.37 | gold quality |
| jejunal mucosa | UBERON:0000399 | 82.35 | gold quality |
| lower esophagus mucosa | UBERON:0035834 | 82.24 | gold quality |
| calcaneal tendon | UBERON:0003701 | 81.64 | gold quality |
| bone marrow | UBERON:0002371 | 80.37 | gold quality |
| embryo | UBERON:0000922 | 80.18 | gold quality |
| ganglionic eminence | UBERON:0004023 | 79.30 | gold quality |
| penis | UBERON:0000989 | 78.74 | gold quality |
| prostate gland | UBERON:0002367 | 78.18 | gold quality |
| oral cavity | UBERON:0000167 | 77.38 | gold quality |
| vagina | UBERON:0000996 | 76.54 | gold quality |
| tonsil | UBERON:0002372 | 76.34 | gold quality |
| blood | UBERON:0000178 | 76.22 | gold quality |
| pylorus | UBERON:0001166 | 76.12 | gold quality |
| esophagus squamous epithelium | UBERON:0006920 | 75.85 | gold quality |
| epithelium of esophagus | UBERON:0001976 | 74.97 | gold quality |
| trachea | UBERON:0003126 | 74.74 | gold quality |
| esophagus mucosa | UBERON:0002469 | 74.44 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | no | 0.00 |
Regulation
Is transcription factor: no
Literature-anchored findings (GeneRIF, showing 2)
- Histone H2B antimicrobial peptides participate in the colonic defense against bacteria and fungi. (PMID:12860195)
- glucose-glycolysis-uH2B signal pathway is well conserved from yeast to mammalian cells, providing an evolutionarily-conserved regulatory mechanism of histone modifications. (PMID:21130743)
Cross-species orthologs
0 orthologs
Paralogs (21): H2BW2 (ENSG00000101812), H2BW1 (ENSG00000123569), H2BC11 (ENSG00000124635), H2BC1 (ENSG00000146047), H2BC5 (ENSG00000158373), H2BC4 (ENSG00000180596), H2BC21 (ENSG00000184678), H2BC13 (ENSG00000185130), H2BC26 (ENSG00000196890), H2BC12 (ENSG00000197903), H2BC18 (ENSG00000203814), H2BC15 (ENSG00000233822), H2BC12L (ENSG00000234289), H2BC14 (ENSG00000273703), H2BC6 (ENSG00000274290), H2BC17 (ENSG00000274641), H2BC9 (ENSG00000275713), H2BC3 (ENSG00000276410), H2BC7 (ENSG00000277224), H2BC10 (ENSG00000278588), H2BK1 (ENSG00000285480)
Protein
Protein identifiers
Histone H2B type 1-C/E/F/G/I — P62807 (reviewed: P62807)
Alternative names: Histone H2B.1 A, Histone H2B.a, Histone H2B.g, Histone H2B.h, Histone H2B.k, Histone H2B.l
All UniProt accessions (2): P62807, B2R4S9
UniProt curated annotations — full annotation on UniProt →
Function. Core component of nucleosome. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling. Has broad antibacterial activity. May contribute to the formation of the functional antimicrobial barrier of the colonic epithelium, and to the bactericidal activity of amniotic fluid.
Subunit / interactions. The nucleosome is a histone octamer containing two molecules each of H2A, H2B, H3 and H4 assembled in one H3-H4 heterotetramer and two H2A-H2B heterodimers. The octamer wraps approximately 147 bp of DNA. Interacts with VRK1; the interaction is mediated by the nucleosome acidic patch, a cluster of negatively charged residues of H2A and H2B forming a cleft within the nucleosome core.
Subcellular location. Nucleus. Chromosome.
Post-translational modifications. Monoubiquitination at Lys-35 (H2BK34Ub) by the MSL1/MSL2 dimer is required for histone H3 ‘Lys-4’ (H3K4me) and ‘Lys-79’ (H3K79me) methylation and transcription activation at specific gene loci, such as HOXA9 and MEIS1 loci. Similarly, monoubiquitination at Lys-121 (H2BK120Ub) by the RNF20/40 complex gives a specific tag for epigenetic transcriptional activation and is also prerequisite for histone H3 ‘Lys-4’ and ‘Lys-79’ methylation. It also functions cooperatively with the FACT dimer to stimulate elongation by RNA polymerase II. H2BK120Ub also acts as a regulator of mRNA splicing: deubiquitination by USP49 is required for efficient cotranscriptional splicing of a large set of exons. Phosphorylation at Ser-37 (H2BS36ph) by AMPK in response to stress promotes transcription. Phosphorylated on Ser-15 (H2BS14ph) by STK4/MST1 during apoptosis; which facilitates apoptotic chromatin condensation. Also phosphorylated on Ser-15 in response to DNA double strand breaks (DSBs), and in correlation with somatic hypermutation and immunoglobulin class-switch recombination. GlcNAcylation at Ser-113 promotes monoubiquitination of Lys-121. It fluctuates in response to extracellular glucose, and associates with transcribed genes. ADP-ribosylated by PARP1 or PARP2 on Ser-7 (H2BS6ADPr) in response to DNA damage. H2BS6ADPr promotes recruitment of CHD1L. Mono-ADP-ribosylated on Glu-3 (H2BE2ADPr) by PARP3 in response to single-strand breaks. Poly ADP-ribosylation on Glu-36 (H2BE35ADPr) by PARP1 regulates adipogenesis: it inhibits phosphorylation at Ser-37 (H2BS36ph), thereby blocking expression of pro-adipogenetic genes. Crotonylation (Kcr) is specifically present in male germ cells and marks testis-specific genes in post-meiotic cells, including X-linked genes that escape sex chromosome inactivation in haploid cells. Crotonylation marks active promoters and enhancers and confers resistance to transcriptional repressors. It is also associated with post-meiotically activated genes on autosomes. Lactylated in macrophages by EP300/P300 by using lactoyl-CoA directly derived from endogenous or exogenous lactate, leading to stimulates gene transcription.
Similarity. Belongs to the histone H2B family.
RefSeq proteins (1): NP_003509* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR000558 | Histone_H2B | Family |
| IPR007125 | H2A/H2B/H3 | Domain |
| IPR009072 | Histone-fold | Homologous_superfamily |
| IPR055333 | HISTONE_H2B_site | Conserved_site |
Pfam: PF00125
UniProt features (110 total): modified residue 91, helix 4, cross-link 4, sequence conflict 2, strand 2, initiator methionine 1, chain 1, sequence variant 1, mutagenesis site 1, region of interest 1, compositionally biased region 1, glycosylation site 1
Structure
Experimental structures (PDB)
76 structures, top 30 by resolution.
| PDB | Method | Resolution (Å) |
|---|---|---|
| 6ACO | X-RAY DIFFRACTION | 1.71 |
| 7R5R | ELECTRON MICROSCOPY | 2.44 |
| 8OX0 | ELECTRON MICROSCOPY | 2.52 |
| 9Y46 | ELECTRON MICROSCOPY | 2.59 |
| 10XZ | ELECTRON MICROSCOPY | 2.6 |
| 7PII | ELECTRON MICROSCOPY | 2.68 |
| 7U46 | ELECTRON MICROSCOPY | 2.68 |
| 10YA | ELECTRON MICROSCOPY | 2.7 |
| 10YC | ELECTRON MICROSCOPY | 2.7 |
| 8OOP | ELECTRON MICROSCOPY | 2.7 |
| 8OX1 | ELECTRON MICROSCOPY | 2.7 |
| 9Y47 | ELECTRON MICROSCOPY | 2.74 |
| 10YB | ELECTRON MICROSCOPY | 2.8 |
| 10YD | ELECTRON MICROSCOPY | 2.8 |
| 8OO7 | ELECTRON MICROSCOPY | 2.8 |
| 5GT0 | X-RAY DIFFRACTION | 2.82 |
| 6X59 | ELECTRON MICROSCOPY | 2.98 |
| 7TAN | ELECTRON MICROSCOPY | 3 |
| 8VWU | ELECTRON MICROSCOPY | 3 |
| 6SEG | ELECTRON MICROSCOPY | 3.1 |
| 7U51 | ELECTRON MICROSCOPY | 3.1 |
| 8QZM | ELECTRON MICROSCOPY | 3.1 |
| 8VWS | ELECTRON MICROSCOPY | 3.1 |
| 9DWF | ELECTRON MICROSCOPY | 3.1 |
| 9EOZ | ELECTRON MICROSCOPY | 3.1 |
| 7A08 | ELECTRON MICROSCOPY | 3.11 |
| 9NQU | ELECTRON MICROSCOPY | 3.16 |
| 8OOA | ELECTRON MICROSCOPY | 3.18 |
| 7UV9 | ELECTRON MICROSCOPY | 3.2 |
| 8X15 | ELECTRON MICROSCOPY | 3.2 |
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-P62807-F1 | 87.94 | 0.68 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (95): 6, 6, 6, 6, 7, 12, 12, 12, 12, 12, 12, 13, 13, 13, 15, 16, 16, 16, 16, 17 …
Glycosylation sites (1): 113
Mutagenesis-validated functional residues (1):
| Position | Phenotype |
|---|---|
| 114 | no effect on interaction with vrk1. |
Function
Pathways and Gene Ontology
Reactome pathways
58 pathways
| ID | Pathway |
|---|---|
| R-HSA-110328 | Recognition and association of DNA glycosylase with site containing an affected pyrimidine |
| R-HSA-110329 | Cleavage of the damaged pyrimidine |
| R-HSA-110330 | Recognition and association of DNA glycosylase with site containing an affected purine |
| R-HSA-110331 | Cleavage of the damaged purine |
| R-HSA-1221632 | Meiotic synapsis |
| R-HSA-171306 | Packaging Of Telomere Ends |
| R-HSA-1912408 | Pre-NOTCH Transcription and Translation |
| R-HSA-201722 | Formation of the beta-catenin:TCF transactivating complex |
| R-HSA-212300 | PRC2 methylates histones and DNA |
| R-HSA-2299718 | Condensation of Prophase Chromosomes |
| R-HSA-2559580 | Oxidative Stress Induced Senescence |
| R-HSA-2559582 | Senescence-Associated Secretory Phenotype (SASP) |
| R-HSA-2559586 | DNA Damage/Telomere Stress Induced Senescence |
| R-HSA-3214815 | HDACs deacetylate histones |
| R-HSA-3214847 | HATs acetylate histones |
| R-HSA-427359 | SIRT1 negatively regulates rRNA expression |
| R-HSA-427389 | ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression |
| R-HSA-427413 | NoRC negatively regulates rRNA expression |
| R-HSA-5250924 | B-WICH complex positively regulates rRNA expression |
| R-HSA-5334118 | DNA methylation |
| R-HSA-5578749 | Transcriptional regulation by small RNAs |
| R-HSA-5617472 | Activation of anterior HOX genes in hindbrain development during early embryogenesis |
| R-HSA-5625886 | Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 |
| R-HSA-5689880 | Ub-specific processing proteases |
| R-HSA-5693565 | Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks |
| R-HSA-5693571 | Nonhomologous End-Joining (NHEJ) |
| R-HSA-5693607 | Processing of DNA double-strand break ends |
| R-HSA-606279 | Deposition of new CENPA-containing nucleosomes at the centromere |
| R-HSA-68616 | Assembly of the ORC complex at the origin of replication |
| R-HSA-69473 | G2/M DNA damage checkpoint |
MSigDB gene sets: 229 (showing top):
REACTOME_MEIOTIC_RECOMBINATION, VERHAAK_AML_WITH_NPM1_MUTATED_DN, REACTOME_DNA_REPLICATION, REACTOME_SIGNALING_BY_NOTCH, GOBP_ANTIMICROBIAL_HUMORAL_RESPONSE, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, REACTOME_MEIOTIC_SYNAPSIS, REACTOME_G2_M_DNA_DAMAGE_CHECKPOINT, GOZGIT_ESR1_TARGETS_DN, HASLINGER_B_CLL_WITH_11Q23_DELETION, GOBP_ORGAN_OR_TISSUE_SPECIFIC_IMMUNE_RESPONSE, REACTOME_ADHERENS_JUNCTIONS_INTERACTIONS, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, GOBP_INNATE_IMMUNE_RESPONSE_IN_MUCOSA, ZHAN_V2_LATE_DIFFERENTIATION_GENES
GO Biological Process (6): innate immune response in mucosa (GO:0002227), nucleosome assembly (GO:0006334), antibacterial humoral response (GO:0019731), defense response to Gram-positive bacterium (GO:0050830), antimicrobial humoral immune response mediated by antimicrobial peptide (GO:0061844), defense response to bacterium (GO:0042742)
GO Molecular Function (5): DNA binding (GO:0003677), structural constituent of chromatin (GO:0030527), identical protein binding (GO:0042802), protein heterodimerization activity (GO:0046982), protein binding (GO:0005515)
GO Cellular Component (7): nucleosome (GO:0000786), obsolete extracellular space (GO:0005615), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytosol (GO:0005829), extracellular exosome (GO:0070062), chromosome (GO:0005694)
Reactome top-level categories
Rollup of top-12 pathways:
| Category | Pathways |
|---|---|
| Cellular Senescence | 3 |
| Depyrimidination | 2 |
| Depurination | 2 |
| Epigenetic regulation of gene expression | 2 |
| Chromatin modifying enzymes | 2 |
| Negative epigenetic regulation of rRNA expression | 2 |
| Positive epigenetic regulation of rRNA expression | 2 |
| Meiosis | 1 |
| Telomere Maintenance | 1 |
| Pre-NOTCH Expression and Processing | 1 |
| TCF dependent signaling in response to WNT | 1 |
| Mitotic Prophase | 1 |
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| antimicrobial humoral response | 2 |
| defense response to bacterium | 2 |
| chromatin | 2 |
| cellular anatomical structure | 2 |
| mucosal immune response | 1 |
| innate immune response | 1 |
| chromatin organization | 1 |
| nucleosome organization | 1 |
| protein-DNA complex assembly | 1 |
| defense response | 1 |
| response to bacterium | 1 |
| nucleic acid binding | 1 |
| structural molecule activity | 1 |
| protein binding | 1 |
| protein dimerization activity | 1 |
| binding | 1 |
| protein-DNA complex | 1 |
| intracellular membrane-bounded organelle | 1 |
| nuclear lumen | 1 |
| cytoplasm | 1 |
| extracellular vesicle | 1 |
| intracellular membraneless organelle | 1 |
Protein interactions and networks
STRING
0 interactions, top by confidence (×1000):
IntAct
113 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| H2AZ1 | ZNHIT1 | psi-mi:“MI:0914”(association) | 0.770 |
| ANP32E | H2AZ1 | psi-mi:“MI:0914”(association) | 0.770 |
| ANP32E | H2AZ1 | psi-mi:“MI:0915”(physical association) | 0.770 |
| TP53BP1 | H2AC11 | psi-mi:“MI:0915”(physical association) | 0.670 |
| H2AC11 | UBB | psi-mi:“MI:0915”(physical association) | 0.650 |
| MAPK7 | PFDN6 | psi-mi:“MI:0914”(association) | 0.640 |
| HIP1 | HIP1R | psi-mi:“MI:0914”(association) | 0.640 |
| FH | H2AZ1 | psi-mi:“MI:0914”(association) | 0.620 |
| H2BC10 | TP53BP2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| H2BC10 | AP2M1 | psi-mi:“MI:0915”(physical association) | 0.560 |
BioGRID (1779): HIST1H2BC (Two-hybrid), HIST1H2BG (Affinity Capture-RNA), HIST1H2BG (Affinity Capture-RNA), HIST1H2BD (Affinity Capture-MS), HIST1H2BD (Affinity Capture-MS), HIST1H2BD (Reconstituted Complex), HIST1H2BG (Reconstituted Complex), HIST1H2BF (Reconstituted Complex), HIST1H2BE (Reconstituted Complex), HIST1H2BI (Reconstituted Complex), HIST1H2BC (Reconstituted Complex), TPX2 (Proximity Label-MS), SMCHD1 (Proximity Label-MS), KIF23 (Proximity Label-MS), KIF4A (Proximity Label-MS)
ESM2 similar proteins: A0A2R8Y619, O97484, P02284, P02285, P02286, P02287, P02288, P04255, P04913, P07794, P07795, P0C1H4, P16888, P16889, P16890, P19374, P21897, P23527, P27326, P30757, P33778, P35067, P35068, P35069, P48557, P57053, P62807, P62808, P70696, P83863, Q00715, Q00729, Q16778, Q27894, Q32L48, Q5QNW6, Q5R893, Q5RCP8, Q64475, Q64478
Diamond homologs: A0A2R8Y619, A2WKT1, A2WKT4, A2WWU2, A2XF66, A2YWI3, A3AGM4, O22582, O60814, O65819, P02281, P02283, P02284, P02285, P02286, P02287, P02288, P02289, P02290, P04255, P06145, P06899, P06900, P07794, P07795, P0C1H3, P0C1H4, P0C1H5, P10853, P10854, P14001, P16888, P16889, P16890, P17271, P19374, P21897, P23527, P27326, P27807
SIGNOR signaling
2 interactions.
| A | Effect | B | Mechanism |
|---|---|---|---|
| SLBP | “up-regulates quantity by expression” | H2BC4 | “translation regulation” |
| “MSL acetyltransferase” | “down-regulates activity” | H2BC4 | monoubiquitination |
Enriched among interaction partners
Reactome pathways and GO biological processes over-represented among this gene’s 101 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.
Reactome pathways:
| Pathway | Partners | Fold | FDR |
|---|---|---|---|
| Activation of NF-kappaB in B cells | 5 | 12.6× | 5e-03 |
| Signaling by ALK fusions and activated point mutants | 6 | 11.6× | 2e-03 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | 6 | 11.3× | 2e-03 |
| Deposition of new CENPA-containing nucleosomes at the centromere | 5 | 10.2× | 8e-03 |
| B-WICH complex positively regulates rRNA expression | 6 | 9.3× | 5e-03 |
| Oxidative Stress Induced Senescence | 8 | 9.3× | 1e-03 |
| Senescence-Associated Secretory Phenotype (SASP) | 7 | 8.9× | 2e-03 |
| Processing of DNA double-strand break ends | 6 | 8.8× | 5e-03 |
GO biological processes:
| GO term | Partners | Fold | FDR |
|---|---|---|---|
| heterochromatin formation | 5 | 15.0× | 3e-03 |
| chromatin remodeling | 11 | 9.4× | 1e-05 |
| regulation of apoptotic process | 9 | 8.8× | 2e-04 |
| negative regulation of apoptotic process | 11 | 4.5× | 3e-03 |
Disease & clinical
Clinical variants and AI predictions
ClinVar
14 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 14 |
| Likely benign | 0 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
92 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 6:26216543:CGA:C | donor_gain | 0.9100 |
| 6:26216537:T:A | donor_gain | 0.9000 |
| 6:26216507:A:AC | donor_gain | 0.7300 |
| 6:26216542:A:AC | donor_gain | 0.7200 |
| 6:26216543:C:CC | donor_gain | 0.7200 |
| 6:26216563:G:A | donor_gain | 0.6700 |
| 6:26216538:C:CA | donor_gain | 0.6600 |
| 6:26216544:G:GT | donor_gain | 0.6400 |
| 6:26216485:A:T | acceptor_gain | 0.6200 |
| 6:26216567:T:TA | donor_gain | 0.6200 |
| 6:26216506:TAGC:T | donor_gain | 0.6100 |
| 6:26216524:CA:C | donor_gain | 0.6100 |
| 6:26216505:TTAGC:T | donor_gain | 0.6000 |
| 6:26216630:G:C | donor_gain | 0.6000 |
| 6:26216416:G:A | donor_gain | 0.5900 |
| 6:26216521:A:T | donor_gain | 0.5600 |
| 6:26216484:CAG:C | acceptor_gain | 0.5500 |
| 6:26216544:G:C | donor_gain | 0.5500 |
| 6:26216554:G:A | donor_gain | 0.5500 |
| 6:26216559:T:TA | donor_gain | 0.5500 |
| 6:26216525:A:C | donor_gain | 0.5400 |
| 6:26216523:A:AC | donor_gain | 0.5300 |
| 6:26216524:C:CC | donor_gain | 0.5300 |
| 6:26216471:T:TG | acceptor_gain | 0.5100 |
| 6:26216533:G:C | donor_gain | 0.5100 |
| 6:26216509:C:T | donor_gain | 0.5000 |
| 6:26216598:TGGA:T | donor_gain | 0.4900 |
| 6:26216283:TGGTG:T | donor_gain | 0.4500 |
| 6:26216510:ACCTT:A | acceptor_gain | 0.4400 |
| 6:26216513:T:TG | acceptor_gain | 0.4400 |
AlphaMissense
810 scored. Top likely-pathogenic:
dbSNP variants (sampled 300 via entrez): RS1002538521 (6:26216563 G>A,C), RS1002793227 (6:26217725 T>C), RS1002799030 (6:26216322 C>A,T), RS1002951859 (6:26218119 T>A,C,G), RS1006613157 (6:26218200 G>A,C), RS1006759405 (6:26217577 C>A,T), RS1010491655 (6:26215878 A>C,G,T), RS1012510149 (6:26217554 T>G), RS1012883659 (6:26217386 C>A,G,T), RS1012932322 (6:26218157 C>G,T), RS1013482436 (6:26218529 T>C), RS1013609205 (6:26217766 A>G), RS1014862039 (6:26217598 TA>T), RS1014881034 (6:26216139 T>C), RS1014914245 (6:26217474 C>G,T)
Disease associations
OMIM: gene MIM:602798 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
14 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST004521_113 | Autism spectrum disorder or schizophrenia | 3.000000e-19 |
| GCST004521_142 | Autism spectrum disorder or schizophrenia | 2.000000e-09 |
| GCST004521_169 | Autism spectrum disorder or schizophrenia | 4.000000e-14 |
| GCST004521_69 | Autism spectrum disorder or schizophrenia | 8.000000e-24 |
| GCST004521_83 | Autism spectrum disorder or schizophrenia | 1.000000e-13 |
| GCST007294_143 | Body fat distribution (trunk fat ratio) | 5.000000e-29 |
| GCST007294_82 | Body fat distribution (trunk fat ratio) | 1.000000e-48 |
| GCST007295_120 | Body fat distribution (leg fat ratio) | 2.000000e-46 |
| GCST007295_91 | Body fat distribution (leg fat ratio) | 1.000000e-26 |
| GCST008839_582 | Height | 2.000000e-55 |
| GCST010141_1 | Beef consumption | 7.000000e-13 |
| GCST010143_19 | Meat-related diet | 5.000000e-13 |
| GCST010143_31 | Meat-related diet | 7.000000e-09 |
| GCST010143_5 | Meat-related diet | 4.000000e-09 |
EFO canonical traits (2, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0004341 | body fat distribution |
| EFO:0008111 | diet measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
51 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| (+)-JQ1 compound | decreases expression, increases expression | 8 |
| sodium arsenite | decreases expression, increases expression | 3 |
| Benzo(a)pyrene | decreases expression, increases expression | 3 |
| Copper | affects binding, decreases expression, increases expression | 2 |
| Formaldehyde | increases expression | 2 |
| Silicon Dioxide | increases expression | 2 |
| Tetrachlorodibenzodioxin | increases expression | 2 |
| 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | increases expression | 2 |
| Aflatoxin B1 | increases expression, affects expression | 2 |
| methyleugenol | decreases expression | 1 |
| bisphenol A | decreases expression | 1 |
| 2-methyl-4-isothiazolin-3-one | increases expression | 1 |
| hydroxyhydroquinone | increases expression | 1 |
| tris(1,3-dichloro-2-propyl)phosphate | decreases expression | 1 |
| cobaltous chloride | decreases expression | 1 |
| 2,3-bis(3’-hydroxybenzyl)butyrolactone | affects cotreatment, decreases expression | 1 |
| maleic acid | decreases expression | 1 |
| abrine | increases expression | 1 |
| Grape Seed Proanthocyanidins | affects cotreatment, increases expression | 1 |
| 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine | increases response to substance, increases expression | 1 |
| licochalcone B | increases expression | 1 |
| incobotulinumtoxinA | decreases expression | 1 |
| NSC 689534 | affects binding, increases expression | 1 |
| PCI 5002 | affects cotreatment, increases expression | 1 |
| Resveratrol | affects cotreatment, decreases expression | 1 |
| Acetaminophen | increases expression | 1 |
| Air Pollutants | increases abundance, increases expression | 1 |
| Berberine | decreases expression | 1 |
| Catechin | affects cotreatment, increases expression | 1 |
| Coumestrol | affects cotreatment, decreases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.